Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy by V. E. Syutkin, V. P. Chulanov, I. V. Karandashova, V. A. Dolgin, A. O. Chugunov

Subjects: Get full text

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study by D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo

Subjects: Get full text

Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen by Andrew Trigg, Eric Chan, Helen Kitchen, Tom Willgoss, Kai Fai Ho, Renee Pierson, Jane Scott

“…**Methods:** PRO data were pooled from three Phase IIb and III trials evaluating interferon-free simeprevircontaining regimens for treatment of chronic HCV infection. …”
Get full text

Inhibition of STING-mediated type I IFN signaling by African swine fever virus DP71L by Lakmal Ranathunga, Sachini Abesinghe, Ji-Won Cha, Niranjan Dodantenna, Kiramage Chathuranga, Asela Weerawardhana, D. K. Haluwana, Nuwan Gamage, Jong-Soo Lee

Subjects: Get full text

Efficacy and safety of new protease inhibitor faldaprevir in treatment of hepatitis C by M. V. Mayevskaya, M. S. Zharkova, V. T. Ivashkin

Subjects: “…treatment modes without interferon…”
Get full text

Alternative splicing expands the antiviral IFITM repertoire in Chinese rufous horseshoe bats. by Nelly S C Mak, Jingyan Liu, Dan Zhang, Jordan Taylor, Xiaomeng Li, Kazi Rahman, Feiyu Chen, Siddhartha A K Datta, Kin Kui Lai, Zhengli Shi, Nigel Temperton, Aaron T Irving, Alex A Compton, Richard D Sloan

“…Species-specific interferon responses are shaped by the virus-host arms race. …”
Get full text

Timosin alpha-1 immunomodulating properties by M. V. Mayevskaya

“…Combination of Timosin alpha-1 and interferon-a (IFN-a) induces substantial increase of IL-2 level and blocks elevation of IL-10 level invoked by IFN-a that can be successfully utilized in chronic hepatitis B (CHB) treatment. …”
Get full text

B-cell non-Hodgkin's lymphoma in the patient with chronic hepatitis C and mixed cryoglobulinemia by V. S. Adonyeva, Ye. A. Kolodyazhnaya, A. B. Bochkarev

“…Presence of mixed cryoglobulinemia within symptomatics of chronic HCV-infection, long history of infection were indicative of HCV-associated lymphoma development. Treatment: interferon-æ2b 3 million IU per day, ribavirin 1000 mg per day. …”
Get full text

The prognostic value of ferritinemia level in patients with chronic hepatitis C by N. C. Sargsyants, E. H. Grigoryan

“…To study the effect of various factors on the blood ferritin level in patients with chronic hepatitis C (CHC) and baseline ferritin level on treatment response rate of pegilated interferon α-2a (PEG-IFN α-2a) combined to ribavirin (RBV). …”
Get full text

Genes of Inflammation and Placental Function GWAS Associated with Idiopathic Recurrent Miscarriage in the Kazakh Population by Alexandra Murtazaliyeva, Gulnara Svyatova, Galina Berezina, Gulfairuz Urazbayeva, Aigerim Sadyrbekova

“…Other studied polymorphisms in the genes of ILs, interferon, P53 proapoptotic protein, kinase domain receptor and STAT3 transcription activator were not associated with RM. …”
Get full text

Triple antiviral therapy in patient with liver cirrhosis: complications and options of pharmacological treatment by M. V. Mayevskaya, I. N. Tikhonov, V. T. Ivashkin

“…Nowadays thrombopoietin receptors agonist (eltrombopag) which allows to provide interferon-based AVT to patients with thrombocytopenia and to optimize it, is developed and approved for clinical application. …”
Get full text

Chronic hepatitis B and risk of kidney involvement by M. V. Mayevskaya, I. N. Tikhonov, V. T. Ivashkin

“…Moreover, renal disease may be caused by medications used for CHB treatment, e.g. direct nephrotoxicity of adefovir or tenofovir, alpha interferon-induced glomerulonephritis, etc. Relation of HBV-infection to periarteritis nodosa - necrotizing vasculitis, ischemic nephropathy is known. …”
Get full text

Modern modes of chronic hepatitis B treatment in daily clinical practice by M. V. Mayevskaya, M. A. Morozova, S. A. Ondos, V. T. Ivashkin

“…At application of pegilated interferon (PEG-IFN) resistance does not develop, however frequency of adverse events is high. …”
Get full text

Hyperferritinemia at the patient with chronic hepatitis C by Ye. N. German, A. O. Buyeverov, M. V. Mayevskaya, Ch. S. Pavlov, V. T. Ivashkin, A. A. Levina

“…., 38 years, despite of rapid virologic response at combined antiviral therapy by pegilated interferon α-2а and ribavirin, had persistently high activity of transaminases and initially high level of serum ferritin increase twice.Conclusion. …”
Get full text

Two ways to one goal: new strategy of antiviral therapy for chronic hepatitis C by S. N. Batskikh

“…New algorithms of antiviral therapy for patients infected by the 1-st virus genotype not treated earlier, and after treatment failure, implicate presence or absence of so-called «induction phase», the kernel of which is application of pegilated interferon-α and ribavirin combination at the beginning of treatment with subsequent addition of the third agent (the direct action antiviral agent). …”
Get full text

Antiviral therapy for chronic hepatitis C: is there a time to change existing standards? by D. T. Abdurakhmanov

“…At CHC patients with the rapid virologic response (absence of viremia at the 4-th week) it is possible to limit duration of treatment by pegilated interferon and ribavirin in the case of the 1-st HCV genotype to 24 wks, in the case of the 2 and 3-rd genotypes to 12–16 wk. …”
Get full text

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program by V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina

“…Before official registration of interferon-free treatment modes in 2015 experience of the application was limited to clinical trials or treatment within early approach programs. …”
Get full text

ACSL4 promotes the formation of the proliferative subtype in hepatoblastoma by Wei Dang, Qin Li, Xiaoying Wang

“…Mechanistically, ACSL4 was found to promote cell proliferation by downregulating the interferon response signaling pathway which may implicate contribution to immunosuppression in the tumor. …”
Get full text

Efficacy and safety of 3D-therapy at HCV-related subcompensated liver cirrhosis (genotype 1b) by P. O. Bogomolov, M. V. Matsiyevich, A. O. Buyeverov, V. D. Beznosenko, Ye. V. Fedosova, M. Yu. Petrachenkova, S. V. Koblov, K. Yu. Kokina, O. S. Kuzmina, N. V. Voronkova

“…To estimate efficacy and safety of 3D mode of interferon­free therapy in patients with subcompensated liver cirrhosis (LC) of HCV etiology (genotype 1b). …”
Get full text

Distinguishing rheumatoid arthritis from psoriatic arthritis by Joseph F Merola, Luis R Espinoza, Roy Fleischmann

“…In PsA, levels of interleukin (IL)-1β, IL-6, IL-17, IL-22, IL-23, interferon-γ and tumour necrosis factor-α (TNF-α) are elevated, and in RA, levels of IL-1, IL-6, IL-22, IL-33, TNF-α, chemokine ligand 11 and chemokine C-X-C motif ligand 13 are elevated. …”
Get full text